Volume 24, Issue 105, September - October, 2020

Examining the adherence of simvastatin prescription in diabetic patients: a descriptive study at Hera General Hospital Makkah (HGH)

Majd Alharazi¹, Nouf Almalki¹, Hetaf Alhabashi¹, Rahaf Felemban¹, Raghad Qasim¹, Asala Assas², May Almutairi¹, Mayam Alharthy¹, Raghad Alsharif¹, Yosra Alhindi³

¹Pharm D graduate, Faculty of pharmacy, University of Umm Al-Qura, Makkah, KSA
²B.Pharm D graduate, Faculty of pharmacy, University of Umm Al-Qura, Makkah, KSA
³Assistant Professor in Clinical Pharmacy, Faculty of Pharmacy, University of Umm Al-Qura, Makkah, KSA

ABSTRACT

Introduction: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality. In the gulf countries specially in Saudi Arabia Diabetes type 2 is becoming the highest in the world, affecting around 30% of adults. In fact, diabetes is associated with an increased risk of cardiovascular disease (CVD). The management of high lipid levels in diabetes is a key aspect within the multifactorial technique to save CVD in people with type 2 diabetes. Several meta-analysis studies have in reality validated the effects of statin remedy. Aims: To look into the adherence of simvastatin in patients with type 2 diabetes. Methods: A descriptive case looking at 1680 diabetic patients conducted in Hera General Hospital. Data were retrieved from clinical files from January 2018 until December 2018. Data evaluation performed using the SPSS software. Results: Almost 95 percent of the population around was older than 45 years. Almost all patients (97%) were on statin therapy. Treatment goal for an LDL less than 2.5 mmol/l was found in (20%) patients. Diabetic men were more likely than diabetic women to receive a statin prescription (P<0.05). Conclusion: Data from 2018 showed that diabetic HGH patients showed only a small proportion of patients with diabetes have met the LDL treatment goal this was mainly because of poor adherence. This underline the need for better monitoring, better use of available medicines and new treatment options for better quality of life.

Keywords: Simvastatin, Diabetes type 2, CVD, Dyslipidemia.

Medical Science, 2020, 24(105), 2918-2924

PDF